Targeted Immunotherapy Small biotech with a focus on STaRT-engineered MSC therapies (MSC1/MSC2) for cancer and inflammatory diseases, presenting a compelling niche for partnering on immunomodulatory cell therapies and related adjuncts.

Lead Candidate Focus Lead program CMB-200 targeting acute optic neuritis and multiple sclerosis precursor states suggests a potential collaboration in neuroinflammation and ophthalmic indications, opening discussions with clinical research networks and patient advocacy groups.

Clinical & Preclinical Evidence Proprietary STaRT technology claims safety and efficacy signals in preclinical models across oncology and inflammatory diseases, offering a platform for co-development, translational studies, and shared risk-reduction opportunities.

Early-Stage Scale Fit Small team (2-10 employees) with revenue under $1M indicates strategic partnerships for manufacturing, regulatory consulting, and CRO/CMO support to accelerate development and clinical trial readiness.

Technical Collaboration Tech stack and digital presence show modern web and SEO readiness; potential for joint marketing, investor outreach, and technology licensing discussions to extend STaRT capabilities and expand pipeline partnerships.